NON-CONFIDENTIAL
INVESTMENT SUBMISSION COVER PAGE
Prior to submitting an investment opportunity to MABA, please first review our Investment Criteria
document – to ensure that there is a fit, and attach this cover page to your executive summary (which
should not exceed three pages).
Please make sure that this application contains only non-confidential information.
Also, please be aware of MABA’s Presenting Company Warrant Requirements:
MABA does not charge companies a cash fee to present. Nor does it get a free grant of equity.
In return for the opportunity to present to MABA, MABA receives from the company the right to invest
in the company, but only if MABA investors invest at least $250,000. While this right may never have
any value if the company is unable to achieve its goals, should the company successfully accomplish
what it has set out to do, the right to invest gives MABA the opportunity to benefit along with other
investors.
Specifically, the company gives MABA the right to invest up to $30,000 in the company, if MABA
members invest at least $250,000 in the company in the 12 month period following the company's
presentation, with the type of security and the price MABA can buy determined by whatever investors
accept in the next round. MABA can take up to 7 years to make that investment.
In reality, if the company is successful, a liquidity event would likely occur before the expiration of the 7
year time horizon, while chances are that the right may never be exercised and that it will have no value,
if the company does not succeed or there is no suitable liquidity event.
Please call us if you have any questions or concerns about this requirement. By submitting an
application, you acknowledge your acceptance of the terms noted above. Once we receive your
application, we will send you a Presenting Company Agreement. Qualified companies will only be
invited to present after we receive a signed copy of that agreement.
We look forward to receiving your submission.
1.
Name of company (plus website – if any)
2.
Name of main contact (name, title, phone(s) & email)
3.
Location of company (if virtual, location of main
contact)
INTRODUCTION
4.
What is the problem your company is trying to solve?
5.
Please describe your company’s solution to the
problem, above, in plain English.
6.
Company start-up date
FUNDING
7.
Amount of money previously raised (total)
8.
Date last round closed
9.
Post-money valuation at the last round
10. Amount of money being raised in current round
11. Pre-money valuation for current round
12. Date current round began & amount of money
invested so far
13. Including the current round, how much more
investment capital will be required (including all
future rounds and not including grants or other nondilutive funding)?
14. What event will render further funding unnecessary
(e.g., licensing deal, breakeven achieved, other) – and
time to reach that event?
15. How do you plan to exit (e.g., IPO, purchase by a
large company), and what is the time anticipated to
reach that point?
16. Describe non-dilutive or grant funding already
received or applied for (please differentiate between
received and applied for)
PRODUCT
17. Is this a single product/service or a platform?
18. If the company has developed a platform, what is the
first product/service to be marketed commercially?
19. Please provide a non-confidential description of how
your product works
20. Please provide data in support of the product’s
efficacy
21. Please indicate at least one significant publication
that you believe supports your technology. (Be
specific. If possible, please attach to submission)
22. Are there toxicity or other issues associated with
your product?
23. Please list the reasons your product is superior to the
standard of care, and to competitors’ products
(including those pending approval)
24. Current development stage (of first product/service)
25. Briefly describe how product/device will be
manufactured
MARKET
26. Total addressable market (if platform – for first
product only)
27. Please identify all your known competitors
28. In addition to patients, please identify all entities
(doctors, hospitals, insurance companies, etc.) that
would benefit from your product – financially and
otherwise, please indicate how they would benefit,
and their reasons to support the product’s adoption
29. Sales and Go-to-Market Strategy
30. If already selling – annual $ sales and number of
customers
31. Please identify current & anticipated alliance
partners (please be specific)
INTELLECTUAL PROPERTY (IP)
32. Describe the status and scope of patent protection, if
any (number of applications, nature of claims, when
filed/granted)
33. Is there other IP – that might affect the
product/service?
34. Who owns the patents and other IP, if any?
35. Describe the competitive IP landscape and how the
company’s IP fits within that landscape
REGULATORY & REIMBURSEMENT
36. FDA strategy, time to approval of primary
indication/first product and approval pathway
37. Reimbursement strategy (one sentence)
TEAM
38. Management team (P&L/operating experience,
significant accomplishments, prior fundraising
experience and return to investors (If any))
39. Endorsement(s)/key supporters/key opinion leaders
(specific names)
40. Professional advisors (specific names) (legal,
accounting, regulatory consultants, others?)
41. Describe all special deals and circumstances with and
between partners, related parties and anyone else
(grant backs to founders, special licenses, etc.)
42. Current salary and other compensation for each
executive. How will it change after financing?
43. Are any of the team members related to one another
(if so, how)?
MISCELLANEOUS
44. How can investors lose their money? What are the
biggest risks (competitive, regulatory, technical, etc.)
standing between the company and successful
commercialization and exit?
45. Anticipated use of funds from this point forward
46. How did you hear of MABA?
47. If you have a short video (<5min) that you would like
to share, please provide the link here.
48. If you have applied to MABA in the past and were
rejected, please list the reasons given for your
rejection, and why these no longer apply.
Please return this completed document - with your company name incorporated into the document
name, along with an executive summary, to [email protected]
Thank you.
Mid Atlantic Bio Angels (MABA)